Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 216

Sort by

Sort Order Select

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Blood (2024) 144 (Supplement 1): 7236.

https://doi.org/10.1182/blood-2024-197883

Published: 2024

Journal Articles

Promising Safety and Efficacy of Eque-Cel Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients: Primary Real World Data from a Single Center

Yan Xu, Gang An, Wei LIU, Qi Wang, Yi Wang, Shuaishuai Zhang, Wenjie Xiong, Tengteng Yu, Mingwei Fu, Shuhua Yi, Lugui Qiu, Dehui Zou

Blood (2024) 144 (Supplement 1): 7228.

https://doi.org/10.1182/blood-2024-209328

Published: 2024

Journal Articles

A Phase Ib/II Study of Trovocabtagene Autoleucel (C-CAR088), an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Gang An, Yan Xu, Shuhua Yi, Rui Lyu, Jiaqi Huang, Wensi Li, Yiran Zhang, Liping Lan, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7235.

https://doi.org/10.1182/blood-2024-194774

Published: 2024

Journal Articles

MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

Yuting Yan, Yulan Zhou, Weihao Chen, Jun Wang, Tingyu Wang, Ying Yu, Yujiao Jia, Zhen Yu, Lugui Qiu, Fei Li, Shuhua Yi

Blood (2024) 144 (Supplement 1): 4624.

https://doi.org/10.1182/blood-2024-207323

Published: 2024

Journal Articles

Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Shuhua Yi, Tingyu Wang, Fei Li, Jingdong Zhang, Xingli Zou, Yanping Ma, Lugui Qiu

Blood (2024) 144 (Supplement 1): 1875.1.

https://doi.org/10.1182/blood-2024-201175

Published: 2024

Journal Articles

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 494.

https://doi.org/10.1182/blood-2024-205608

Published: 2024

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Blood (2024) 144 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2024-201476

Published: 2024

Journal Articles

Lenalidomide and Obinutuzumab in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Jingjing Yuan, Li Yuxi, Yuting Yan, Xiong Wenjie, Tengteng Yu, Tingyu Wang, Ying Yu, Lugui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 6345.

https://doi.org/10.1182/blood-2024-206886

Published: 2024

Journal Articles

A Prospective Study of Rituximab/Bendamustine and Rituximab/DHAP +/- Zanubrutinib Induction Therapy with or without ASCT in Young Newly Diagnosed Mantle Cell Lymphoma

Hui Wang, Lijie Xing, Dan Liu, Haichen Wei, Ke Lu, Qiang He, Linna Xie, Ji Ma, Lugui Qiu, Zengjun Li

Blood (2024) 144 (Supplement 1): 6307.

https://doi.org/10.1182/blood-2024-206243

Published: 2024

Journal Articles

Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia

Hao Sun, Xia Liu, Maria Luisa Guerrera, Nickolas Tsakmaklis, Amanda Kofides, Andres Felipe Ramirez Gamero, Catherine A. Flynn, Christopher J Patterson, Mu Hao, Lugui Qiu, Shayna R Sarosiek, Jorge J. Castillo, Zachary R Hunter, Shirong Liu, Steven P. Treon

Blood (2024) 144 (Supplement 1): 743.

https://doi.org/10.1182/blood-2024-211488

Published: 2024

Journal Articles

A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

Yan Xu, Zhen Cai, Zhongjun Xia, Chen Yang, Jia Chen, Zewen Zhu, Xiaojuan Jing, Ji Tian, Nating Zhang, Ailing Cui, Jianxing Tang, Haolin Sun, Lugui Qiu

Blood (2024) 144 (Supplement 1): 3381.2.

https://doi.org/10.1182/blood-2024-200737

Published: 2024

Journal Articles

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Chenxing Du, Shuaishuai Zhang, Lugui Qiu, Gang An, Wenqiang Yan, Jian Cui, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou

Blood (2024) 144 (Supplement 1): 7068.

https://doi.org/10.1182/blood-2024-207775

Published: 2024

Journal Articles

Analysis of Diagnosis and Treatment Pattern for Newly Diagnosed Multiple Myeloma in China over 20 Years

Jingyu Xu, Yuntong Liu, Wenqiang Yan, Lingna Li, Rui Lyu, Chenxing DU, Weiwei Sui, Lugui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 6917.

https://doi.org/10.1182/blood-2024-201167

Published: 2024

Journal Articles

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Gang An, Zhuogang Liu, Jie Jin, Zhen Cai, Wei Li, Zhongjun Xia, Xinan Cen, Yu Hu, Jian-Qing Mi, Hongmei Jing, Rong Zhan, Xiaoyan Qu, Xin Du, Dan Gao, Liang Zhao, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7055.

https://doi.org/10.1182/blood-2024-199908

Published: 2024

Journal Articles

Real-World Effectiveness and Safety Analysis of Carfilzomib-Pomalidomide- Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Multicenter Retrospective Study from Eastern Shandong of China

Huishou Fan, Rongxia Wei, Xiangyan Feng, Xin Zhang, Tianlan Li, Lu Liu, Hui Wang, Lingjie Sun, Xue Shi, Hongguo Zhao, Zhao Li, Jingying Cui, Xianqi Feng, Junqing Xu, Junjie Ma, Lugui Qiu, Wei Wang

Blood (2024) 144 (Supplement 1): 7032.

https://doi.org/10.1182/blood-2024-207159

Published: 2024

Journal Articles

TRIM28 Serves As a Key Regulator of Protein Homeostasis and Mediates Proteasome Inhibitor Resistance in Multiple Myeloma

Teng Fang, Lanting Liu, Hao Sun, Xiyue Sun, Zhen Yu, Lugui Qiu, Mu Hao

Blood (2024) 144 (Supplement 1): 4668.

https://doi.org/10.1182/blood-2024-204159

Published: 2024

Journal Articles

Performance and Challenges of the Lymphgen Classification Algorithm in Real-World Clinical Applications

Yujiao Jia, Haoxu Wang, Li Qin, Bingqing Huang, Qi Sun, Huijun Wang, Chengwen Li, Wei Liu, Yan Xu, Shuhua Yi, Lugui Qiu, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6233.

https://doi.org/10.1182/blood-2024-209761

Published: 2024

Journal Articles

Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study

Lugui Qiu, Zhuogang Liu, Shuhua Yi, Thanh Nguyen, Wen-Juan Yu, Keshu Zhou, Haiwen Huang, Udomsak Bunworasate, Man Huynh, Hui Zhou, Su-Peng Yeh, Yiqiu Wang, Xiaofeng Liu, Wei Fu

Blood (2024) 144 (Supplement 1): 3251.

https://doi.org/10.1182/blood-2024-193476

Published: 2024

Journal Articles

26S Proteasome Non-Atpase Subunit 3 (PSMD3/Rpn3) Is a Potential Therapeutic Target in Multiple Myeloma

Teng Fang, Yan Song, Ting Du, Arghya Ray, Xueping Wan, Minxing Wang, Sindhu C Pillai, Md. Abu Musa, Mu Hao, Lugui Qiu, Dharminder Chauhan, Kenneth C. Anderson

Blood (2024) 144 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2024-206000

Published: 2024

Journal Articles

Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Qianru Zhang, Wenqiang Yan, Lu Sun, Guoqing Han, Qiaoli Wu, Yiran Cui, Bolin Liu, Feng Zhang, Ke Pu, Mingchao Zhang, Xiaobing Zhang, Lugui Qiu, Qingguo Li, Gang An, Yuxuan Liu

Blood (2024) 144 (Supplement 1): 1590.

https://doi.org/10.1182/blood-2024-202680

Published: 2024

NARROW

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Promising Safety and Efficacy of Eque-Cel Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients: Primary Real World Data from a Single Center

A Phase Ib/II Study of Trovocabtagene Autoleucel (C-CAR088), an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Lenalidomide and Obinutuzumab in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

A Prospective Study of Rituximab/Bendamustine and Rituximab/DHAP +/- Zanubrutinib Induction Therapy with or without ASCT in Young Newly Diagnosed Mantle Cell Lymphoma

Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia

A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Analysis of Diagnosis and Treatment Pattern for Newly Diagnosed Multiple Myeloma in China over 20 Years

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Real-World Effectiveness and Safety Analysis of Carfilzomib-Pomalidomide- Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Multicenter Retrospective Study from Eastern Shandong of China

TRIM28 Serves As a Key Regulator of Protein Homeostasis and Mediates Proteasome Inhibitor Resistance in Multiple Myeloma

Performance and Challenges of the Lymphgen Classification Algorithm in Real-World Clinical Applications

Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study

26S Proteasome Non-Atpase Subunit 3 (PSMD3/Rpn3) Is a Potential Therapeutic Target in Multiple Myeloma

Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only